Emrock Corporation (531676)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROE of 92.18% indicates high return on book equity, though driven by a very small capital base.
• Piotroski F-Score of 6/9 suggests decent short-term financial health on profitability, leverage, and efficiency metrics.
• Positive book value of ₹4.91 per share provides some asset backing for the current price of ₹18.08.
• Profit growth of 1000% shows recent earnings momentum, even if from a negligible base.
• Market cap of ₹9 Cr makes the company small enough that a genuine operational turnaround could move the needle.

Concerns

• P/E of 517.35 with 0% sales growth and latest quarterly net profit of ₹0 Cr makes the valuation unsupported by fundamentals.
• Current price ₹18.08 is below the 52-week low of ₹25.39 and about 94% below the 52-week high of ₹305.95, indicating severe price deterioration.
• ROCE of only 3.00% versus P/B of 3.68 means investors pay 3.7 times book for very poor return on capital.
• 0% dividend yield, N/A promoter holding, and N/A debt/equity leave shareholders with no income, no clarity on promoter alignment, and no balance-sheet comfort.

AI Analysis

Let me start with what I don't need: a hopeful story. The numbers are enough. Emrock has a market cap of only ₹9 crore and sells for ₹18.08. The 92.18% ROE looks wonderful, but Graham taught me to be suspicious of a number that good. A P/E of 517.35 means the market is paying over five hundred times earnings; on this market cap, that is less than ₹2 lakh of annual profit. The latest quarter shows sales of ₹1 crore and net profit of ₹0 crore. Sales growth is zero. Profit growth of 1000% off a near-nothing base is noise, not a durable franchise. ROCE of 3% tells the real story: the company earns almost nothing on the capital it employs. Book value is ₹4.91, so I am being asked to pay 3.68 times book for a business that generates only 3% return on capital. That is the opposite of a margin of safety. The 52-week range is alarming: from ₹305.95 down to ₹25.39, and now the price is ₹18.08, below the stated low. A quality business doesn't fall 94% in a year. Dividend yield is zero, so there is no income while waiting. Promoter holding is not disclosed, and debt/equity is also N/A, so I cannot judge whether owners are aligned or whether the balance sheet is safe. The Piotroski F-Score of 6/9 is mildly encouraging, but it cannot overcome the valuation and the lack of sales growth. In Buffett's terms, this is a cigar butt with no smoke. It looks small and cheap, but it is actually expensive on earnings and on book. I would rather pass. If this company ever produces consistent sales and real positive net profit quarter after quarter, I will revisit. Until then, the figures fail every test I care about: predictable earnings, strong returns on tangible capital, and a reasonable price. Paying 3.68 times book for 3% ROCE is not value; it is hope.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer